ELGX Endologix Inc

Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today the appointment of Ruth Lyons to the position of Vice President of Global Marketing. Ms. Lyons brings more than 25 years of marketing and business development experience in the medical device industry.

John McDermott, President and Chief Executive Officer of Endologix, said, "Ruth has an exceptional track record of developing and launching innovative new medical technologies. She will play a key role on the Endologix leadership team as we prepare for the global launches of our AFX™, Nellix® and Ventana™ products, and continue to develop our innovative product portfolio. Ruth is a proven leader with significant strategic marketing experience who will help build on our momentum to become the leader in treatments for aortic disorders."

Ms. Lyons said, "Joining Endologix provides me with the opportunity to work with what I believe to be the most innovative company in the market focused on endovascular aortic devices. The Company has a very promising new product pipeline and I look forward to working with the management team to continue driving growth and market share gains."

Ms. Lyons comes to Endologix from St. Jude Medical's Cardiac Rhythmn Management Division, where she spent 10 years in leadership positions in marketing, portfolio planning and business development. Most recently Ms. Lyons held the position of VP Marketing, Emerging Technologies where she had primary responsibilities for all product planning and marketing of new technologies and future growth drivers. Prior to St. Jude Medical, Ms. Lyons held senior marketing positions at Johnson & Johnson's Cordis Cardiology, Biosense Webster and DePuy Orthopaedics divisions as well as 10 years in sales and marketing at Baxter Healthcare. Ms. Lyons has a Masters in Business Administration from the University of Southern California.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. The Nellix® Endovascular System and Ventana™ Fenestrated Stent Graft System are investigational devices. Additional information can be found on Endologix's Web site at www.endologix.com.

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements relating to the development and launch of new products, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the uncertainties related to the introduction and clinical acceptance of new products,. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

CONTACT: COMPANY CONTACT:
         Endologix, Inc.
         John McDermott, CEO
         (949) 595-7200
         www.endologix.com
         
         INVESTOR CONTACTS:
         The Ruth Group
         Nick Laudico (646) 536-7030
         Zack Kubow (646) 536-7020